OTCMKTS:LZAGY Lonza Group (LZAGY) Stock Price, News & Analysis $57.53 -4.74 (-7.61%) (As of 11/15/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendFinancialsHeadlinesInsider TradesSEC FilingsShort Interest About Lonza Group Stock (OTCMKTS:LZAGY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lonza Group alerts:Sign Up Key Stats Today's Range$57.46▼$59.3050-Day Range$60.77▼$65.4352-Week Range$36.71▼$67.00Volume130,145 shsAverage Volume81,513 shsMarket Capitalization$41.55 billionP/E RatioN/ADividend Yield0.33%Price TargetN/AConsensus RatingStrong Buy Company OverviewLonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.Read More… The pin that pops the AI bubble (Ad)My new documentary explores the background to this pattern and how and why I believe it will almost certainly repeat itself with the AI frenzy. I urge you to watch it before you invest another cent. Again, to be clear, I’m no Chicken Little. Far from it. So go here now to read my new report The Big AI Die-Up… while you still can. Lonza Group Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks57th Percentile Overall ScoreLZAGY MarketRank™: Lonza Group scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Lonza Group.Read more about Lonza Group's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth15.57% Earnings GrowthEarnings for Lonza Group are expected to grow by 15.57% in the coming year, from $1.67 to $1.93 per share.Price to Earnings Growth RatioLonza Group has a PEG Ratio of 2.26. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLonza Group has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the outstanding shares of Lonza Group have been sold short.Short Interest Ratio / Days to CoverLonza Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lonza Group has recently decreased by 55.07%, indicating that investor sentiment is improving significantly. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldLonza Group has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthLonza Group does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Lonza Group will have a dividend payout ratio of 9.84% next year. This indicates that Lonza Group will be able to sustain or increase its dividend.Read more about Lonza Group's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the outstanding shares of Lonza Group have been sold short.Short Interest Ratio / Days to CoverLonza Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lonza Group has recently decreased by 55.07%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment0.82 News SentimentLonza Group has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lonza Group this week, compared to 1 article on an average week.Search Interest1 people have searched for LZAGY on MarketBeat in the last 30 days. MarketBeat Follows30 people have added Lonza Group to their MarketBeat watchlist in the last 30 days. This is an increase of 173% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lonza Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.07% of the stock of Lonza Group is held by insiders.Percentage Held by InstitutionsOnly 0.04% of the stock of Lonza Group is held by institutions.Read more about Lonza Group's insider trading history. Receive LZAGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lonza Group and its competitors with MarketBeat's FREE daily newsletter. Email Address LZAGY Stock News HeadlinesLonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing SuitesNovember 13 at 1:50 AM | markets.businessinsider.comLonza Group AG (LZAGY): Among UBS’ Top Tech Based Disruptive Stocks For 2030October 30, 2024 | insidermonkey.comThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly repeat itself with the AI frenzy. I urge you to watch it before you invest another cent. Again, to be clear, I’m no Chicken Little. Far from it. November 16, 2024 | Porter & Company (Ad)Lonza Group Ltd (LONN) Gets a Buy from Kepler CapitalOctober 26, 2024 | markets.businessinsider.comUBS Keeps Their Buy Rating on Lonza Group Ltd (LONN)October 25, 2024 | markets.businessinsider.comPositive Momentum and Strategic Positioning Drive Buy Rating for Lonza Group Ltd.October 25, 2024 | markets.businessinsider.comLonza Q3 Trading In Line To Deliver On FY View; Confirms FY24 OutlookOctober 24, 2024 | markets.businessinsider.comLonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug ConjugatesOctober 22, 2024 | markets.businessinsider.comSee More Headlines LZAGY Stock Analysis - Frequently Asked Questions How have LZAGY shares performed this year? Lonza Group's stock was trading at $42.09 at the beginning of the year. Since then, LZAGY stock has increased by 36.7% and is now trading at $57.53. View the best growth stocks for 2024 here. Does Lonza Group have any subsidiaries? Lonza Group subsidiaries include these companies: Octane Biotech, Micro-Macinazione, Capsugel, PharmaCell, InterHealth Nutraceuticals, Triangle Research Labs, Diacon Technologies, and others. How do I buy shares of Lonza Group? Shares of LZAGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today11/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Tobacco products Sub-IndustryN/A Current SymbolOTCMKTS:LZAGY CUSIPN/A CIK1446711 Webwww.lonza.com Phone(161) 316-8111Fax41-61-316-9111Employees17,834Year Founded1897Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio34.45 P/E Growth2.26Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$7.48 billion Price / Sales5.56 Cash Flow$1.89 per share Price / Cash Flow30.36 Book Value$14.23 per share Price / Book4.04Miscellaneous Outstanding Shares722,260,000Free Float721,756,000Market Cap$41.55 billion OptionableNot Optionable Beta0.99 Social Links 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:LZAGY) was last updated on 11/16/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this BEFORE November 19th.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lonza Group AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Lonza Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.